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Behavioral and electrophysiological studies of Alzheimer’s disease (AD) and other
tauopathies have revealed that the onset of cognitive decline correlates better with
synaptic dysfunctions than with hallmark pathologies such as extracellular amyloid-β
plaques, intracellular hyperphosphorylated tau or neuronal loss. Recent experiments
have also demonstrated that anti-cancer microtubule (MT)-stabilizing drugs can rescue
tau-induced behavioral decline and hallmark neuron pathologies. Nevertheless, the
mechanisms underlying tau-induced synaptic dysfunction as well as those involved in
the rescue of cognitive decline by MT-stabilizing drugs remain unclear. Here we began to
study these mechanisms using the glutaminergic sensory-motoneuron synapse derived
from Aplysia ganglia, electrophysiological methods, the expression of mutant-human tau
(mt-htau) either pre or postsynaptically and the antimitotic drug paclitaxel. Expression
of mt-htau in the presynaptic neurons led to reduced excitatory postsynaptic potential
(EPSP) amplitude generated by rested synapses within 3 days of mt-htau expression,
and to deeper levels of homosynaptic depression. mt-htau-induced synaptic weakening
correlated with reduced releasable presynaptic vesicle pools as revealed by the induction
of asynchronous neurotransmitter release by hypertonic sucrose solution. Paclitaxel
totally rescued tau-induced synaptic weakening by maintaining the availability of the
presynaptic vesicle stores. Postsynaptic expression of mt-htau did not impair the above
described synaptic-transmission parameters for up to 5 days. Along with earlier confocal
microscope observations from our laboratory, these findings suggest that tau-induced
synaptic dysfunction is the outcome of impaired axoplasmic transport and the ensuing
reduction in the releasable presynaptic vesicle stores rather than the direct effects of
mt-htau or paclitaxel on the synaptic release mechanisms.
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INTRODUCTION
Behavioral and electrophysiological studies of Alzheimer’s disease
(AD) and other tauopathies have revealed that the onset of cogni-
tive decline correlates better with synaptic dysfunctions than with
hallmark pathologies such as the accumulation of extracellular
amyloid-β plaques, intra-neuronal neurofibrillary tangles formed
by aberrantly phosphorylated tau, degeneration of neurites or
neuronal loss (Terry et al., 1991; Arriagada et al., 1992; Selkoe,
2002; Coleman and Yao, 2003; Giannakopoulos et al., 2003; Saul
et al., 2013). Nevertheless, the mechanisms by which tau induces
synaptic dysfunctions remain unclear. Studies aimed at elucidat-
ing the underlying mechanisms have drawn on the correlations
between behavioral performance and synaptic structure, synaptic
biochemistry and synaptic electrophysiology. Using transgenic
(Tg) mice exhibiting tau-induced cognitive decline, a number
of studies have indicated that loss of dendritic spine or deple-
tion of synaptic proteins appear prior to hallmark pathologies
(Eckermann et al., 2007; Yoshiyama et al., 2007; Mocanu et al.,
2008; Polydoro et al., 2009; Bittner et al., 2010; Hoover et al., 2010;
Rocher et al., 2010; Crimins et al., 2011; Sydow et al., 2011a,b;
Alldred et al., 2012; Spires-Jones and Knafo, 2012; Kopeikina
et al., 2013). Electrophysiological approaches designed to relate
declined cognition and functional synaptic transmission have
indicated that the expression of pathological mutant-human tau
(mt-htau) leads to synaptic dysfunctions by impairing both pre
and postsynaptic mechanisms (Yoshiyama et al., 2007; Polydoro
et al., 2009; Hoover et al., 2010; Crimins et al., 2012; Hochgrafe
et al., 2013). For example, postsynaptic impairment of long-
term potentiation (LTP) at the CA1–CA3 synapses of rTgP301L
mice is generated by mislocalization and accumulation of hyper-
phosphorylated tau in dendritic spines. This leads in turn to
impaired glutamate receptor trafficking, targeting and anchoring
to the postsynaptic membrane, resulting in impairment of the
postsynaptic cascade associated with LTP (Hoover et al., 2010).
Other postsynaptic mechanisms were also discussed by Ittner
et al. (2010). A number of studies have also shown that prior to
neuronal loss, htau induces synaptic dysfunctions by presynaptic
mechanisms which reduce the probability of neurotransmitter
release (Yoshiyama et al., 2007; Polydoro et al., 2009; Chakroborty
et al., 2012; Tai et al., 2012). The presynaptic mechanisms were
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not investigated in details in these studies and could theoretically
be the outcome of impaired axoplasmic transport or direct tau
interference with the molecular machinery of neurotransmitter
release (Morfini et al., 2009).
Recent behavioral studies complemented by biochemical and
histological observations suggest that antimitotic drugs such as
paclitaxel or epothilone D can rescue Tg tau mice from devel-
oping symptomatic behavioral decline and may even reverse it
(Michaelis et al., 2002; Ballatore et al., 2007, 2012; Brunden et al.,
2009, 2010a,b, 2012; Zhang et al., 2012). The rescue and putative
therapeutic effects of these antimitotic drugs are attributed to
their microtubule (MT) stabilizing function which counteracts
MT destabilization by tau phosphorylation (Lee et al., 1994).
In a recent series of live confocal microscope studies our
laboratory demonstrated that cultured Aplysia neurons can serve
as a cell biological platform to document and analyze cellular
pathologies induced by human tau and its rescue by paclitaxel
(Shemesh et al., 2008; Shemesh and Spira, 2010a, 2011). We
showed that the expression of wild type or mt-htau in cultured
Aplysia neurons leads to (1) the swelling of axonal segments
(Stokin et al., 2005); (2) translocation of tau to submembrane
domains (Brandt et al., 1995); (3) reduction in the number of
MTs along the axon; (4) the reversal of their polar orientation
(Shemesh et al., 2008; Shemesh and Spira, 2010a); (5) impaired
organelle transport (Stamer et al., 2002); (6) dramatic accumula-
tion of macro-autophagosomes (Nixon et al., 2008; Shemesh and
Spira, 2010b); (7) compromised neurite morphology (Kraemer
et al., 2003); and (8) degeneration (Wittmann et al., 2001). In
addition, using this cellular platform, we found that bath appli-
cation of 10 nM paclitaxel prior to the onset of mt-htau induced
pathological processes rescued the neurons from undergoing the
cell pathologies described above. Higher concentrations of pacli-
taxel (100 nM) did not prevent the unfolding of the pathologies
(Shemesh and Spira, 2011).
In the present study we used the classical glutaminergic
sensory-motorneuron (SN-MN) synapse derived from Aplysia
californica (Kandel, 2001) to further explore the fundamental
mechanisms underlying tau-induced synaptic dysfunctions and
better understand the effects of MT-stabilizing drugs in pre-
venting it. The SN-MN synapse has proven to be extremely
useful in studies of the mechanisms underlying different forms of
short-, intermediate- and long-term synaptic plasticity (Kandel,
2001; Bailey and Kandel, 2008; Glanzman, 2009; Jin et al., 2011;
Mayford et al., 2012). Specifically, we examined the effects of a
double mutant- tau containing both missense mutations P301S
and K257T (Goedert and Jakes, 2005; Shemesh et al., 2008;
Shemesh and Spira, 2010a, 2011) on three well characterized
parameters of the SN-MN synapse: (a) the strength of synaptic
transmission as indicated by the amplitude of the excitatory
postsynaptic potential (EPSP) in a rested synapse; (b) the rate and
levels of homosynaptic depression; and (c) the extent to which a
single bath application of 5-Hydroxytryptamine creatinine sulfate
complex (5HT) induces facilitation of a depressed synapse. Esti-
mation of the releasable vesicle pool size revealed that expression
of mt-htau in the presynaptic neuron reduces the pool size, and
leads to weakening of the synaptic functions. Expression of mt-
htau postsynaptically for up to 5 days did not lead to alteration in
the synaptic functions. Paclitaxel (10 nM) in the culture medium
rescued the synapse from the pathological changes.
MATERIALS AND METHODS
CELL CULTURES
Sensory neurons from the pleural ganglia of adult animals
(60–80 g) were cocultured with L7 or left siphon (LFS) postsy-
naptic motor neurons from the abdominal ganglia of juvenile
(2–5 g), or adult (100 g) specimens as described by Schacher
and Proshansky (1983). Briefly, animals (imported from the NIH
marine resources facility at the University of Miami, Fl, USA) were
anesthetized by injection of isotonic MgCl2 solution. The ganglia
were isolated and incubated for 1.5–3 h in 0.1% protease (protease
type XIV Sigma) at 34◦C. The ganglia were then desheathed,
and the cell bodies with their long axons were pulled out with
sharp micropipettes and placed on poly-L-lysine-coated (Sigma)
glass bottom culture dishes. The culture medium consisted of (in
volume) 10% filtered hemolymph from Aplysia faciata collected
along the Mediterranean coast, 40% L-15 (Sigma) supplemented
for marine species and 50% artificial sea water (ASW, see below).
Twenty-four hours after plating the dishes were transferred to
an 18◦C incubator. Intracellular microinjections of mRNA and
application of paclitaxel to the bathing solution took place on
the 3rd day after plating and the electrophysiological experiments
were conducted 6–8 days after plating.
ELECTROPHYSIOLOGY
Intracellular recording and stimulation by sharp glass electrodes
were performed at room temperature in artificial sea water
composed of NaCl 460 mM, KCl 10 mM, CaCl2 10 mM,
MgCl2 55 mM, and HEPES [N-(2-hydroxyethyl)piperazine-N′-2-
ethanesulfonic acid, Sigma] 11 mM, adjusted to pH 7.6.
The electrodes were filled with 2M KCl and had a resistance of
5–9 M. Evoked EPSPs were recorded while holding the motor
neuron transmembrane potential at approximately−55 mV.
Spontaneous miniature potentials were rarely recorded in cul-
ture formed by a single sensory neuron in contact with a single L7
neuron, but could be recorded using the SN-LFS synapse.
For the electrophysiological experiments the pre and postsy-
naptic neurons were impaled by sharp microelectrodes that were
used for both current injection and voltage recordings. In each
experimental session we always included control synaptic pairs in
which the sensory neurons were isolated from the same adult ani-
mals as those used for the experimental groups; similarly, the L7
motoneurons were prepared from the same batch of juvenile ani-
mals. In a series of preliminary experiments conducted every day
following the injection of mt-htau encoding mRNA we observed
that the effect on synaptic transmission was detectable on the 3rd
day of mRNA injection and therefore concentrated the documen-
tation of the synaptic functions on the 3rd day of mRNA injection.
To estimate the size of the releasable vesicle pool we used the
SN-LFS synapses and a modified protocol developed by Zhao
and Klein (2002, 2004). Briefly, to maximize the availability of
vesicles to be released, the synapses were exposed to 20 nM
phorbol 12,13-dibutyrate (PDBu) solution for 1 min. then 50 µl
of hypertonic sucrose solution (1 M) was added from a pipette
onto the cells. This led within approximately 1 s to asynchronous
Frontiers in Cellular Neuroscience www.frontiersin.org February 2014 | Volume 8 | Article 34 | 2
Erez et al. Paclitaxel counteracts tau-induced synaptic pathology
release of synaptic potentials at high frequency for a duration
of a few minutes. Since the amplitude of the unitary synaptic
potentials ranged between 0.2–2.5 mV it was assumed that a
fraction of the potentials reflected multi-quantal release events
(Zhao and Klein, 2002). Because the release frequency in some
experiments was very high the unitary events summated to a level
where individual events could not be discerned. For that reason
we estimated the hypertonic sucrose solution-releasable vesicle-
pool-size by measuring the integral of voltage over time of the
asynchronous release. Measurements were conducted for 20 s,
starting 1 s after the application rather than by counting the peak
of the individual events. Calculation of the integral asynchronous
release was done using in-house software.
mRNA PREPARATION AND INJECTION
mRNAs were transcribed in vitro using the recombinant tran-
scription system as described elsewhere by our laboratory (Sahly
et al., 2003). Double mt-htau containing both missense mutations
P301S and K257T (Shemesh et al., 2008) was cloned in a pCS2+
expression vector as previously reported . The transcribed mRNAs
were pressure-injected into the cell body cytoplasm of the pre
or postsynaptic cultured neurons 3 days after plating, when the
synaptic contact between the cells were already established and
had reached steady state strength as described earlier in Sahly et al.
(2003).
CONFOCAL MICROSCOPE IMAGING
The systems used for confocal imaging included a Nikon C1
system mounted on a Nikon TE-2000 Eclipse microscope with a
Nikon plan-Apo chromat 60x 1.4 NA oil objective. The system
was equipped with three lasers: blue diode (405 nm), argon (488
nm) and green HeNe (543 nm). Images were collected and pro-
cessed using EZ-C1 software at 20–24◦C as previously described
(Shemesh et al., 2008; Shemesh and Spira, 2011). Cherry-tagged
mt-htau was excited at 543 nm; the emitted fluorescence was col-
lected using a 605/75 nm filter. Green fluorescent protein (GFP)-
tagged mt-htau was excited at 488 nm; the emitted fluorescence
was collected using a 515/30 nm filter. Cerulean tagged mt-htau
was excited at 405 nm; the emitted fluorescence was collected
using a 485/30 nm filter.
DRUGS
Paclitaxel (Sigma-Aldrich) and phorbol 12,13-dibutyrate (PDBu
-Sigma) were stored in a stock solution of Dimethyl Sulfoxide
(DMSO) at a concentration of 10 mM, diluted to a concentration
of 10 and 20 µM in ASW (respectively) and further diluted to
a working concentration of 10 and 20 nM (respectively) at the
culture dish. The DMSO concentration never exceeded 0.002% in
the culture dish. 5-Hydroxytryptamine creatinine sulfate complex
(5HT, Sigma) was prepared fresh on the day of the experiments.
A stock solution of 10 mM was diluted in double distilled water
(DDW), and then diluted to a final concentration of 10 µM
in ASW.
STATISTICAL ANALYSIS
The effects of various treatments are presented as the percent
change of EPSP amplitude after treatment with respect to the ini-
tial EPSP amplitude before treatment. All the data are presented as
mean ± standard error of the mean (SEM). t-tests and ANOVAs
were performed using Excel software.
RESULTS
THE EFFECTS OF mt-HUMAN TAU EXPRESSION AND PACLITAXEL ON
SYNAPTIC PROPERTIES
To characterize the effects of mt-htau on synaptic transmission
and examine the potential use of paclitaxel to counteract it we
studied four experimental groups: (a) a control group of cocul-
tured presynaptic sensory neurons and L7 postsynaptic motor
neurons. In this group the presynaptic neurons were injected on
day 3 in culture with KCl or were not injected; (b) a group of
synaptic pairs in which the presynaptic neurons were injected on
day 3 in culture with mRNA encoding GFP-, cerulean-, or cherry-
tagged double mutant-human tau containing missense mutations
P301S and K257T (Shemesh et al., 2008); (c) like group b, but
1–2 h after tagged mt-htau mRNA microinjection, paclitaxel at
a final concentration of 10 nM was added to the culture solution;
and (d) the presynaptic neuron not injected with mt-htau mRNA,
but rather exposed to 10 nM paclitaxel from day 3 after culturing.
All groups were subjected to electrophysiological experiments
in which the resting potential, input resistances (Rin) and three
synaptic parameters were monitored: (a) the amplitude of the
first EPSP generated by rested synaptic pairs; (b) the time course
and level of homosynaptic depression as revealed by delivery of
40 intracellular stimuli evoking presynaptic action potentials at
0.05 Hz; and (c), the extent to which a single bath application of
10 µM 5HT induced facilitation of the depressed synapse.
Confocal imaging revealed that the translational products of
the injected tagged mt-htau mRNA reached detectable levels in
the cytoplasm within 4 h of injection. Twenty-four hours later the
fluorescently tagged mt-htau was well expressed throughout the
entire sensory neuron. Using confocal imaging of the MTs and
axonal transport, we documented in an earlier study (Shemesh
et al., 2008) that initial impairments of the axoplasmic transport
can be imaged within 24 h of the mRNA injection. With time the
axoplasmic transport was further reduced.
The resting potentials of the pre and postsynaptic neurons
were found to be similar in the control and experimental groups
(Table 1). Whereas the averaged Rin of the presynaptic neurons
expressing mt-htau and bathed in paclitaxel, and the averaged Rin
in paclitaxel treated neurons are higher than the averaged input
resistances of the control and mt-htau expressing neurons, the
differences are statistically not significant (Table 1 row 3, P = 0.28
and P = 0.35 respectively).
Comparison of the amplitude of the first EPSP generated by
stimulation of rested synaptic pairs (Figure 1) revealed that in
synaptic pairs expressing presynaptic mt-htau the average first
EPSP amplitude was significantly reduced by 41.62 ± 9.39%
in comparison to the control EPSPs (for SN-L7 synapses from
12.82 ± 1.14 to 7.89 ± 1.65 mV, n = 19 and 22 for control
and mt-htau respectively, α = 0.05, p = 0.0191 and for SN-LFS
synapses from 22.78 ± 2.19 to 11.7 ± 2.43 mV, n = 19 and 10 for
control and mt-htau respectively, α = 0.05, p = 0.0026. t-test for
the normalized results of all synapses, for unequal variances, n =
38 and 32 for control and mt-htau respectively, α = 0.005, p =
0.00057). In neurons that were not injected with mt-htau mRNA
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Table 1 | Electrophysiology parameters of the pre- and postsynaptic neurons.
Control mt-htau mt-htau & Paclitaxel Paclitaxel
Presynaptic resting −40.87 ± 2.43 −38 ± 2.37 −42 ± 1.24 −37.5 ± 1.34
potential (mV) n = 8 n = 6, p = 0.41 n = 9, p = 0.69 n = 8, p = 0.25
Postsynaptic (L7) −53.91 ± 0.8 −56.88 ± 1.61
resting potential (mV) n = 11 n = 16, p = 0.11
Presynaptic Input 54.57 ± 5.54 57.37 ± 8.21 71.69 ± 13.62 72.73 ± 17.33
resistance (M) n = 12 n = 8, p = 0.78 n = 7, p = 0.28 n = 6, p = 0.35
Postsynaptic (L7) 26.67 ± 4.96 19.8 ± 1.62
Input resistance (M) n = 7 n = 12, p = 0.29
Miniature potential 0.22 ± 0.02, 0.22 ± 0.03,
amplitude (mV) n = 205, 5 cells n = 119, 6 cells
Presynaptic spike 97.12 ± 1.66, 93.38 ± 2.08, 93.51 ± 3.38, 92.46 ± 6.73,
amplitude (mV) n = 8 n = 8, p = 0.18 n = 9, p = 0.36 n = 4, p = 0.29
Presynaptic spike 2.59 ± 0.09 2.37 ± 0.13 2.37 ± 0.18 2.39 ± 0.2
duration (msec) n = 14 n = 8, p = 0.22 n = 9, p = 0.31 n = 7, p = 0.39
Calcium peak (1F/F0) 0.65 ± 0.07 0.79 ± 0.04 1.17 ± 0.22 0.66 ± 0.12
Presynaptic neuron n = 6 n = 5, p = 0.11 n = 5, p = 0.08 n = 7, p = 0.87
and bathed in 10 nM paclitaxel for 3 days the average amplitude
of the first EPSP was similar to that of the average control EPSPs
(Figure 1) (t-test for normalized results of SN-L7 and SN-LFS
synapses, for unequal variances, n = 38 and 48 for control and
paclitaxel respectively, α = 0.05, p = 0.27). In synapses formed by
presynaptic neurons expressing mt-htau and continuously bathed
in 10 nM paclitaxel the amplitude of the first EPSP was signif-
icantly higher than in mt-htau expressing presynaptic neurons
(t-test for normalized results of SN-L7 and SN-LFS synapses,
for unequal variances, n = 32 and 25 for tau and tau+paclitaxel
respectively, α = 0.005, p = 0.00087) but not significantly higher
than the average control EPSPs (t-test for normalized results
of SN-L7 and SN-LFS synapses, for unequal variances, n = 38
and 25 for control and tau+paclitaxel respectively, α = 0.05,
p = 0.28).
In summary these experiments revealed that presynaptic
expression of mt-htau leads within 3 days of expression to
decreased amplitude of the first EPSP evoked in rested synapses,
and that this effect is impeded by the continuous presence of
10 nM paclitaxel in the culture medium (from day 3 onward,
Figure 1).
Next we examined the effects of presynaptic mt-htau expres-
sion on: (1) the rate of homosynaptic depression (throughout
the 40 stimuli); (2) the degree of synaptic depression (average
of stimuli 38–40); and (3) the degree of 5HT-induced facilitation
(average of stimuli 43–45). To that end, the EPSPs were depressed
by 40 consecutive stimuli delivered at 0.05 Hz to the presynaptic
sensory neuron in the four experimental groups. Then, 10 µM
5HT was added to the bathing solution and ten additional EPSPs
were measured (Figure 2). In all groups the overall rates of
the normalized homosynaptic depression curves were statistically
similar (repeated-measures ANOVAs: interaction effect between
control and tau—α = 0.05, F(39,720) = 0.45, p = 0.998; interac-
tion effect between control and paclitaxel—α = 0.05, F(39,720) =
0.61, p = 0.971; the interaction effect between control and
tau+paclitaxel—α = 0.05, F(39,720) = 0.33, p = 0.999; and the inter-
action effect between paclitaxel and tau+paclitaxel—α = 0.05,
F(39,720) = 0.7, p = 0.918 and between tau and tau+paclitaxel—
α = 0.05, F(39,720) = 0.35, p = 0.999).Nevertheless, the final degree
of the normalized synaptic depression value was affected by mt-
htau and ameliorated by paclitaxel (Figure 2B). In the control
experiments, 40 stimuli depressed the EPSP to 24.76 ± 3% of
the first EPSP (n = 10). In tau expressing presynaptic neurons
the EPSP was depressed to 14.96 ± 3.38% of the first EPSP
(significantly lower than the control, t-test for unequal variances,
n = 10 and 11 for control and tau respectively, α = 0.05, p = 0.043,
Figure 2). In the mt-htau expressing presynaptic neuron cultured
in the presence of paclitaxel the value of the depressed EPSP was
similar to the control, 21.23 ± 1.7% of the initial level (t-test for
unequal variances, n = 10 and 11 for control and tau+paclitaxel
respectively, α = 0.05, p = 0.32). In paclitaxel alone the depressed
EPSP value did not significantly differ from the control, at
22.62 ± 2.03% of the initial level (t-test for unequal variances,
n = 10 and 14 for control and paclitaxel respectively, α = 0.05,
p = 0.56).
Following homosynaptic depression of the control synapses,
5HT application led to the recovery of the EPSP amplitude to
74.65 ± 9.45% of the initial level (n = 9) (Figure 2B). In the
mt-htau expressing presynaptic neurons 5HT application led to
recovery of the depressed EPSP amplitude to a lower average
level of 43.75 ± 8.83% with respect to the initial amplitude
(this value was significantly different from the control, t-test for
unequal variances, n = 9 and 11 for control and tau respectively,
α = 0.05, p = 0.028). In synapses formed between presynaptic
neurons expressing mt-htau that were continuously bathed in
10 nM paclitaxel, the 5HT application induced EPSP facilitation
to 65.9 ± 11.5% of the initial level (t-test for unequal variances,
n = 11 and 8 for tau and tau+paclitaxel respectively, α = 0.05,
p = 0.15; t-test for equal variances, n = 9 for control and 8 for
tau+paclitaxel respectively, α = 0.05, p = 0.56). Finally, in synapses
bathed in 10 nM paclitaxel for 3 days 5HT induced synaptic
facilitation to a value closer to the control 61.38 ± 5.26% of the
initial level (t-test for unequal variances, n = 9 and 15 for control
and paclitaxel respectively, α = 0.05, p = 0.24).
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FIGURE 1 | Decreased EPSP amplitude by the expression of
presynaptic mt-htau for 3 days and its rescue by 10 nM paclitaxel.
Shown are the normalized amplitudes of the first EPSP generated in rested
synaptic pairs (SN-L7 and SN-LFS synapses). In blue, control—the EPSPs
generated by synaptic pairs cultured for 6 days. In red, the first EPSP
generated by the stimulation of a mt-htau expressing presynaptic neuron
injected on day 3 in culture with fluorescently tagged mt-htau mRNA. The
evoked EPSP was monitored 3 days later. In green, the first EPSP
generated by synaptic pairs exposed on the 3rd day in culture to 10 nM
paclitaxel for 3 days. In magenta, the EPSP generated by synaptic pairs
expressing fluorescently tagged mt-htau for 3 days while being bathed in 10
nM paclitaxel since the injection of mt-htau mRNA.
In conclusion, presynaptic expression of mt-htau reduced the
EPSP amplitude generated by stimulation of a rested synapse
(Figures 1, 2), led to a greater level of homosynaptic depression
and reduced 5HT-induced synaptic dishabituation (Figure 2). 10
nM paclitaxel in the culture medium rescued all these forms of
mt-tau-induced syatnaptic weakening.
MECHANISMS UNDERLYING MUTANT-HUMAN TAU-INDUCED
SYNAPTIC PATHOLOGY
Recent studies have suggested that tauopathies may spread across
synapses from one neuron to another (Frost and Diamond, 2010;
Wu et al., 2013). Therefore, in examining possible mechanisms
to account for the synaptic weakening by presynaptic expres-
sion of mt-tau we considered both pre and postsynaptic mech-
anisms. Theoretically the postsynaptic mechanisms could include
reduced resting potential of the motoneuron, reduced input
resistance, reduced receptor density and/or receptor conductance.
The presynaptic mechanisms could include decreased transient
elevation of the free intracellular calcium concentration following
the firing of a presynaptic action potential, reduced amounts
of readily releasable vesicle store, or impairments of the release
machinery.
Since the resting potential, input resistance of L7 and the
amplitude of the miniature potentials recorded from LFS neurons
were not significantly altered in synapses expressing presynaptic
mt-htau (Table 1) it is reasonable to assume that within the time
frame of the experiments, presynaptic expressing of mt-htau did
not induce anterograde trans synaptic alterations.
Therefore, we examined whether presynaptic expression of
mt-htau reduces evoked release by impairing the mechanism
of the spike generated voltage dependent calcium influx. To
that end, we recorded the presynaptic action potential by intra-
cellular microelectrodes inserted into the cell body and the
associated transient elevation of the free intracellular calcium
concentrations by confocal microscope imaging of fluo-4 from
the axon of isolated sensory neurons or sensory neurons form-
ing synaptic contact with L7. These observations revealed that
mt-htau expression did not interfere with the spike genera-
tion mechanisms and the ensuing transient elevation of the
bulk free intracellular calcium levels in presynaptic neuron
(Table 1).
An alternative hypothesis to account for the impaired synap-
tic transmission is that mt-htau expression interferes with the
mechanisms of vesicle translocation from the reserve store to the
readily releasable pool and/or from the cell body to the synaptic
terminals. Earlier studies showed that in cultured Aplysia SN-L7
neurons, PDBu application leads to vesicle mobilization from a
reserve pool to a readily releasable one (Gingrich and Byrne, 1985;
Hochner et al., 1986; Bailey and Chen, 1988; Braha et al., 1990;
Dale and Kandel, 1990; Ghirardi et al., 1992; Manseau et al., 2001;
Khoutorsky and Spira, 2005). To examine the first hypothesis
we compared the time course and maximal amplitude of PDBu
induced EPSP facilitation in moderately depressed synapses of
control and mt-htau expressing neurons (Figure 3). In the experi-
ments we applied four presynaptic stimuli that partially depressed
the control synapses to 55.26 ± 5.39% and the presynaptically
expressing mt-htau neurons to 40.26 ± 3.44% of the first EPSP.
Then 20 nM PDBu was applied to the bathing solution. This
led to increased EPSPs amplitudes in both the control and the
experimental synaptic pairs with no significant difference between
the two (t-test for unequal variances, n = 4 and 7 for control
and mt-htau respectively, α = 0.05, p = 0.24, average of stimulus
7–9). In both, the maximal EPSP amplitude was reached after
five stimuli (100 s). These observations suggested that vesicle
mobilization activated by PDBu was not impaired by mt-htau
expression.
ESTIMATION OF THE CHANGES IN THE VESICLE POOL SIZE INDUCED
BY MUTANT-HUMAN TAU EXPRESSION AND PACLITAXEL
The observations described above could reflect partial depletion
of vesicle stores (Bykhovskaia, 2011) at the presynaptic terminal
due to mt-htau-induced impairment of the axoplasmic transport
(Shemesh and Spira, 2011). To examine this hypothesis and test
whether paclitaxel prevents such reduction from occurring, we
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FIGURE 2 | The effects of presynaptic expression of mt-htau on
homosynaptic depression kinetics, 5HT induced facilitation of the
depressed synapse and the rescue of mt-htau-induced synaptic
functions by paclitaxel. All recordings were made on day 6 in culture.
(A) Raw average data. (B) Normalized results. Blue- control neurons.
Red- mt-htau expressing presynaptic neurons for 3 days (days 4–6).
Green- synaptic pairs bathed from day 4 to 6 in 10 nM paclitaxel.
Magenta- synaptic pairs that express presynaptic mt-htau and cultured in
the presence of paclitaxel from day 4 to 6. Arrowhead- time of 5HT
application.
estimated the amount of transmitter stores in the presynaptic
terminals by bath application of hypertonic sucrose solution. In
earlier publications Zhao and Klein (2002, 2004) showed that this
technique can be used to assess the vesicle pool size in cultured
Aplysia neurons, as in other synapses (Rosenmund and Stevens,
1996; Zhao and Klein, 2002, 2004).
In the experiments, presynaptic SNs and postsynaptic LFS
neurons were cocultured for 3 days and the four experimental
groups and protocols described above were tested. In each exper-
iment we first applied a single stimulus to the presynaptic neuron
to test whether a functional synapse was indeed established.
To increase the probability of neurotransmitter release, we next
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FIGURE 3 | PDBu induced facilitation of moderately depressed control-
and mt-htau expressing synapses. (A) Raw data. (B) Normalized results.
For the experiments presynaptic neurons expressing mt-htau for 3 days
(from day 4 to 6) were stimulated four times at a rate of 0.05 HZ. Thereafter
PDBu was bath-applied to a final concentration of 20 nM. Note that
although the average absolute amplitude of the EPSP in the mt-htau
expressing synapses is smaller, the rates of synaptic depression and
5HT-induced facilitation were similar in the control (blue) and the
presynaptically expressing mt-htau neurons (red). Arrowhead- time of
application of 20 nM PDBu.
applied 20 nM PDBu to the bathing solution. One minute later,
50 µl of 1 M Sucrose solution was applied to the culture dish
(containing 3 ml ASW). Bath application of 50 µl, 1 M sucrose
led within less than a second to asynchronous release of neu-
rotransmitter that appeared as a barrage of synaptic potentials
representing single vesicles (miniature potentials) as well as multi-
quantal release events (Figure 4). The amplitudes of the asyn-
chronous potentials ranged in different experiments from 0.2 to
2.5 mV. The frequency of release (as estimated by counting the
peaks of the potentials) was in the range of 0.4–16.5 Hz. It should
be noted, however, that at high frequencies the asynchronized
potentials summated (Figure 4A). Therefore, we estimated the
size of the hyperosmotic sucrose-releasable neurotransmitter pool
by measuring the voltage integral of the asynchronized potential
amplitudes over time rather than by counting the peaks of indi-
vidual events (Figure 4B; Zhao and Klein, 2002, 2004).
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FIGURE 4 | Estimation of the releasable presynaptic vesicle pool size in
control, mt-htau expressing presynaptic neurons, and the effects of
paclitaxel. The releasable presynaptic vesicle pool size of four experimental
groups was estimated by monitoring asynchronous postsynaptic potentials
from SN-LFS synapses following bath application of hypertonic sucrose
solution. (A–D) are sample recordings of the sucrose-evoked asynchronous
potentials. (E) The integral of the amplitude of asynchronous release over
time. (A) Control, neurons grown for 6 days in culture (blue in E). (B) The
presynaptic neurons were injected on day 3 in culture with mt-htau mRNA
and tested on day 6 by application of hyper osmotic sucrose solution (red in
E). (C) Neurons exposed to paclitaxel for 3 days (from day 3 to 6) and tested
on day 6 by hyperosmotic sucrose solution (green in E). (D) Like B, but also
exposed to paclitaxel from day 3 (magenta in E). The arrows in A, B, C and D
depict the time of sucrose application. (E) The integral of voltage over time of
the asynchronous release sampled five times over a period of 2 s (10 s),
starting 1 s after the application.
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Using this approach we found that the hypertonic sucrose
solution-releasable vesicle pool size was reduced to 48% in presy-
naptic neurons expressing mt-htau (estimated by the total num-
ber of releases, see Materials and Methods; t-test for unequal
variances, n = 9 and 8 for control and mt-htau respectively, α =
0.05, p = 0.00005). Continuous bathing of the mt-htau expressing
synapses in 10 nM paclitaxel (from day 3 onward) prevented
this from occurring (t-test for unequal variances, n = 9 and 7
for control and tau+paclitaxel respectively, α = 0.05, p = 0.41).
No effects on the sucrose releasable pool size was observed in
synapses incubated in paclitaxel alone (t-test for equal variances,
n = 9 for control and paclitaxel respectively, α = 0.05, p = 0.27)
(Figure 4). These observations are consistent with earlier reports
from our laboratory showing that the expression of mt-htau in
cultured Aplysia neurons leads to impaired axoplasmic transport
and that paclitaxel rescues this from occurring (Shemesh et al.,
2008; Shemesh and Spira, 2010a,b, 2011).
POSTSYNAPTIC EFFECTS OF MUTANT-HUMAN TAU (MT-HTAU)
EXPRESSION
Using identical protocols to those described above for mt-htau
expression by the presynaptic neurons we next examined the
consequences of mt-htau expression by the postsynaptic neurons
L7 on synaptic transmission. Examination of the L7 trans- mem-
brane potential and input resistance (Table 1) did not reveal any
significant effects. Likewise, the EPSP amplitude of a rested con-
trol synapse and postsynaptic mt-htau expressing synapse were
not significantly different (11.53 ± 2.96 and 17.99 ± 3.82 mV,
n = 7 and 13 respectively. t-test for unequal variances, α =
0.05, p = 0.2). The overall rates of the normalized homosynaptic
depression of control synapses and postsynaptic expressing mt-
htau were statistically similar (repeated-measures ANOVAs: inter-
action effect between control and postsynaptic tau—α = 0.05,
F(39,400) = 0.32, p = 0.9999). The degree of synaptic depression
(average of stimuli 38–40) were similar in the control experiments
(21.23 ± 2.54% of the first EPSP) and the tau expressing postsy-
naptic neurons (16.38 ± 3.2%; t-test for unequal variances, n = 6
and 13 for control and postsynaptic tau respectively, α = 0.05, p =
0.25, Figure 5). 5HT-induced heterosynaptic facilitation 3 and 5
days after the injection of mt-htau mRNA to L7 did not reveal
any significant changes from control (Figure 5). In the control the
EPSP amplitude recovered to to 93.24± 25.56% of the initial level
(n = 6) and in the mt-htau expressing postsynaptic neurons 5HT
application led to recovery of the depressed EPSP amplitude to an
average level of 64.29 ± 13.94% (this value were not significantly
different, t-test for unequal variances, n = 6 and 12 for control
and postsynaptic tau respectively, α = 0.05, p = 0.35).
In conclusion, postsynaptic expression of mt-htau does not
affect the presynaptic release properties and short term homosy-
naptic depression which reflect presynaptic mechanisms. Possible
mechanisms to explain the lack of postsynaptic mt-htau expres-
sion on synaptic transmission are discussed below.
DISCUSSION
The main finding of the present study is that within 3 days
of mt-htau expression in the presynaptic neuron the releasable
presynaptic vesicle pool is significantly reduced, resulting in
diminished synaptic transmission. Continuous exposure of the
neurons to 10 nM paclitaxel (from day 3 in culture onward),
a clinically approved anti-neoplastic agent (Jordan and Kamath,
2007), counteracts the development of mt-htau-induced synaptic
transmission dysfunctions. Along with earlier findings from our
laboratory (Shemesh et al., 2008; Shemesh and Spira, 2010a,b,
2011), the present study suggests that tau-induced impaired axo-
plasmic transport may be the cornerstone of the cascade under-
lying presynaptic dysfunctions and that protection of MT by
antimitotic drugs from undergoing mt-htau induced pathology
is sufficient to rescue the neuron from synaptic weakening.
The present study utilized the technical advantages of the
Aplysia cell biological platform to investigate the electrophysiol-
ogy of mt-htau induced synaptic pathology. These include the
ability to express mt-htau either in the pre or postsynaptic neuron,
to intracellularly record and stimulate the pre or postsynaptic
neurons, the ability to express mt-htau at any selected point
in time and to live-image it for an extended period of time.
Earlier studies from our laboratory showed that the cell biological
pathologies induced by mt-htau in cultured Aplysia neurons are
similar to those documented in vertebrates and include reduction
in the number of MTs along the axon, reversal of the MT polar ori-
entation, impaired organelle transport, accumulation of macro-
autophagosomes and lysosomes (Shemesh et al., 2008; Shemesh
and Spira, 2010a,b, 2011). The fundamental electrophysiological
results described here demonstrate for the first time that pacli-
taxel rescues cultured neurons from undergoing mt-htau-induced
synaptic transmission pathology.
Below we discuss possible mechanisms by which mt-human
tau impairs synaptic transmission when expressed presynapti-
cally, how 10 nM paclitaxel counteract tau induced presynaptic
pathophysiology and why postsynaptic expression of mt-htau has
no significant effect on the system as used.
MECHANISMS UNDERLYING SYNAPTIC DYSFUNCTION BY
MUTANT-HUMAN TAU (MT-HTAU) EXPRESSION
Impairment of axoplasmic transport mechanisms is considered a
central common denominator in a variety of neurodegenerative
diseases (Morfini et al., 2009; Riemer and Kins, 2013). It is rea-
sonable to assume that even minor interferences with the steady-
state maintenance of the presynaptic vesicle stores, mitochondria,
other subcellular organelles, and mRNA particles may progres-
sively lead to synaptic and neuronal circuit dysfunction which will
eventually culminate in declined cognition.
The observations described above suggest that within the time
frame of the experiments, mt-htau partially impairs synaptic
functions by interfering with the normal steady-state mainte-
nance of presynaptic vesicle stores. Expression of mt-htau in the
postsynaptic neuron for 5 days did not lead to detectable synaptic
dysfunctions.
The fact that expression of mt-htau in the presynaptic neuron
does not totally block evoked release, and spike-evoked transient
elevation of the intracellular calcium concentration while impair-
ing synaptic strength and plasticity may be related to a gradual
cumulative effect of impaired vesicle transport mechanisms due
to the documented effects of mt-htau on the MT density and polar
orientation (Shemesh et al., 2008; Shemesh and Spira, 2010a).
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FIGURE 5 | The effects of postsynaptic expression of mt-htau on
homosynaptic depression kinetics and 5HT induced facilitation of the
depressed synapse. All recordings were made on day 6 in culture. (A) Raw
data. (B) Normalized results. Control neurons (blue), red- mt-human tau
expressing postsynaptic neurons for 3 days from day 4 to 6 in culture.
Arrowheads indicate the time of 5HT application.
This conclusion is consistent with earlier biochemical studies
of vertebrate neurons showing that tau-hyperphosphorylation
and misfolding impair axoplasmic transport lead to depletion
of essential molecular components at distal neuronal sites (Hall
et al., 2001; Stamer et al., 2002; Coleman and Yao, 2003; Man-
delkow et al., 2003; Baas and Qiang, 2005; Hollenbeck and Saxton,
2005; Thies and Mandelkow, 2007; Cuchillo-Ibanez et al., 2008;
Dixit et al., 2008; Morfini et al., 2009; Stoothoff et al., 2009;
Zempel et al., 2010).
Although tau compromised the absolute amplitudes of EPSPs
and led to a significantly deeper homosynaptic depression, the
kinetics of 5HT or PDBu induced synaptic facilitation were not
altered. Therefore it is reasonable to assume that tau does not have
a direct effect on vesicle mobilization from the reserve stores to the
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readily releasable pool within the presynaptic terminal. Rather, by
interfering with the organelle transport system along the axons,
the steady state processes of maintaining the presynaptic vesicle
pool is disrupted. This interpretation is consistent with the pro-
tective effects of paclitaxel on synaptic function, since paclitaxel
replaces the phosphorylated tau that dissociates from neuronal
MTs (Lee et al., 1994) and thereby maintains their structural and
functional integrity.
In rodent CNS neurons a significant fraction of the presy-
naptic releasable vesicle stores is replenished by local membrane
recycling (Sudhof, 2004; Schweizer and Ryan, 2006) and thus the
vesicle store is partially independent of the anterograde supply
of vesicles. Thus, impairment of presynaptic anterograde vesicle
transport is not expected to lead to immediate depletion of the
releasable neurotransmitter store even if high frequency stimuli
are applied for as long as effective membrane cycling mechanisms
are operative. To the best of our knowledge, in Aplysia SN-MN
membrane cycling at the presynaptic terminal following potas-
sium depolarization has only been documented in a single paper
(Fioravante et al., 2007). Nevertheless, it is not clear to what extent
local membrane cycling mechanism is effective under conditions
of electrical stimulation. Therefore, it is conceivable that depletion
of the presynaptic releasable vesicle pool (by impaired axoplasmic
transport) has a significant effect on synaptic transmission.
The observation that presynaptic mt-htau expression leads to
reduced synaptic transmission but does not impair the release
processes is consistent with studies conducted on htau Tg mice
and drosophila. Based on paired pulse facilitation experiments
and high frequency stimulation to induce LTP, Polydoro et al.
(2009) reported that the Schaffer collateral-CA1 pyramidal cells
synapses of htau Tg mice reveal a decreased probability of neu-
rotransmitter release and lack of LTP. The documented decreased
release probability could be due to a number of mechanisms, one
of which is a reduction in the availability of releasable vesicles
as described here. Electrophysiological experiments conducted
on neuromuscular junctions of Tg drosophila expressing human
tau—0N3R (Chee et al., 2005, 2006) revealed that low frequency
stimulation (1 Hz) of the wild type and Tg fly generate EPSPs
of similar amplitudes. Nevertheless, whereas the EPSP amplitude
generated at high frequency (50 Hz) was sustained by the wild-
type, whereas in the Tg drosophila the EPSP amplitude under-
went significant reduction. Chee et al. (2005, 2006) attributed the
diminished release at high frequencies to impaired axoplasmic
transport of mitochondria to the presynaptic terminals of the
motor neurons, but this could also be due to depletion of vesicle
stores.
Another mechanism that should be considered to account for
reduction in the availability of releasable vesicle store is cluster-
ing of vesicles remote from the release sites by mt-htau. It is
well established that un-phosphorylated synapsin tether synaptic
vesicles to the cytoskeleton and thereby regulate the availability
of neurotransmitter for release (Llinas et al., 1985). Intracellular
microinjection of human tau42 recombinant protein into the
presynaptic terminal of the squid giant synapse significantly
reduced neurotransmitter release when stimulated at high fre-
quencies 30–40 min after its intracellular microinjection (Moreno
et al., 2011). It was suggested that the injected recombinant
human-tau42 protein led to vesicle clustering away from the active
zone concomitant with the reduced vesicle count at the active zone
(reduced readily releasable pool). We cannot rule out that such a
mechanism also contributed to the reduced synaptic functions in
our experiments. Since paclitaxel competes with tau on its MT
binding site it is theoretically possible that it might interfere with
vesicle clustering as well.
WHY ARE THERE NO SIGNIFICANT POSTSYNAPTIC MUTANT-HUMAN
TAU (MT-HTAU) EFFECTS ON THE SENSORY-MOTONEURONS (SN-MN)
SYNAPSE?
Electrophysiological studies conducted on Tg mouse models
have attributed tau-induced synaptic anomalies to postsynaptic
mechanisms generated by mislocalization and accumulation of
hyperphosphorylated tau to the dendritic spines, the impairment
of glutamate receptor trafficking, targeting and anchoring to the
postsynaptic membrane (Hoover et al., 2010; Ittner et al., 2010;
Ittner and Gotz, 2011; Kremer et al., 2011; Pozueta et al., 2013;
Tai et al., 2012; Yu and Lu, 2012; Yu et al., 2012). These processes
depend on the transport of AMPAR containing vesicles into den-
dritic spines and the fusion of the vesicles with the postsynaptic
membrane. Increased tau levels in Tg mice lead to its accumu-
lation together with protein kinase FYN in dendrites where it
phosphorylates NMDA receptors and facilitates its interaction
with the postsynaptic density protein PSD95.
The experimental paradigms used in the present study revealed
the effects of mt-htau and paclitaxel on presynaptic mechanisms.
The observation that postsynaptic expression of mt-htau for up
to 5 days does not affect synaptic transmission may be taken to
imply that: unlike in vertebrate neurons postsynaptic expression
of mt-htau is not effecting postsynaptic mechanisms or that mt-
htau is not transported retrogradely across the synaptic cleft in
large enough quantities to reduce the presynaptic vesicle stores. It
should be noted however that in the Aplysia SN-MN synapse short
term plasticity in the form of homosynaptic depression or short-
term facilitation involve presynaptic mechanisms. In contrast,
intermediate- and long-term synaptic facilitation of the SN-MN
synapse involve postsynaptic mechanisms including modulation
of AMPA receptor trafficking and local protein synthesis (Roberts
and Glanzman, 2003). It is thus conceivable that expression of mt-
htau in the postsynaptic motor neuron would generate postsy-
naptic pathologies on intermediate- and long-term postsynaptic
processes. This possibility was not examined in the present study
and will be the subject of future studies.
IMPLICATIONS OF THE RESULTS FOR CLINICAL APPLICATIONS OF
ANTIMITOTIC DRUGS IN PREVENTING THE PROGRESS OF
TAUOPATHIES
Behavioral studies on rodent models and our earlier cell biolog-
ical studies supported the initial hypothesis of Lee et al. (1994)
that MT stabilizing reagent provide protection in both tau- and
A β-induced neurodegeneration (Michaelis et al., 1998, 2005;
Brunden et al., 2010b, 2012; Shemesh and Spira, 2010a,b, 2011;
Ballatore et al., 2012; Zhang et al., 2012). Because paclitaxel does
not permeate the blood brain barrier, recent efforts have been
directed toward examining the potential use of BBB-permeable
MT stabilizing reagents. These studies demonstrated that the
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MT-stabilizing drug Epotilone D rescue cognitive decline of Tg
mice (Michaelis et al., 2002; Brunden et al., 2009, 2010a,b, 2012;
Ballatore et al., 2012; Zhang et al., 2012). When considering the
use of a MT stabilizing reagent to slow down, protect or even
reverse tau-pathologies it is important to recall that over stabiliza-
tion of dynamic MTs have direct pathological effects on neurons
and other cell types and that the range of safe concentrations
of these drugs may be narrow. In addition, assuming that a safe
concentration can be controlled under in vivo conditions, the
long-term use of these reagents may create secondary problems.
For example, stabilized MTs by exogenous drugs may undergo
acetylation or detyrosination and as a consequence be accessible
to cleavage by endogenous katanin (Peris et al., 2009; Sudo and
Baas, 2010). This may lead to impaired transports and would
require further molecular interventions to control such secondary
damage. Therefore when considering the use of MT stabilizing
reagents for clinical applications these effects should be taken into
consideration.
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